Bevacizumab and Albumin-Bound Paclitaxel Treatment in Metastatic Breast Cancer

doi:10.3816/CBC.2007.n.039

Clinical Breast Cancer

Volume 7, Issue 10, October 2007, Pages 779-783

https://doi.org/10.3816/CBC.2007.n.039 Get rights and content

Abstract

Background

Miller et al demonstrated that the combination of bevacizumab and paclitaxel has significant activity in metastatic breast cancer (MBC). Because albumin-bound paclitaxel has been shown to have less toxicity, a better tumor delivery, and possibly better response for MBC, we combined it with bevacizumab to treat women with MBC.

Patients and Methods

This is a retrospective analysis. Billing records from March 2005 through December 2006 were reviewed to identify all patients treated with a combination of albumin-bound paclitaxel/bevacizumab. A total of 40 women were identified. They received a minimum of 2 courses. Patients with measurable disease were monitored for response using Response Evaluation Criteria in Solid Tumors. Women with bone-only disease were monitored with positron emission tomography (PET)/computed tomography/magnetic resonance imaging and tumor markers. All response data were confirmed by independent review.

Results

Of 33 women with measurable disease, 16 had objective responses to the albumin-bound paclitaxel/bevacizumab regimen (3 complete responses and 13 partial responses) for an overall response rate (ORR) of 48.5%. Median time to progression for responders was 128 days. Another 5 women had stable disease (SD) with a median duration of 135 days. Of 7 patients with bone-only disease, 2 had almost complete resolution of PET activity and 4 had SD (median, 148 days). Toxicity was acceptable with fatigue, neuropathy, pain, and hypertension being the most common complaints.

Conclusion

In our limited series of women with advanced, heavily pretreated MBC treated with albumin-bound paclitaxel/bevacizumab, we saw a 48.5% ORR. The regimen was well tolerated. Randomized studies are needed to confirm efficacy and safety of this combination in treating breast cancer.

References (21)

KD Miller et al.
Breast cancer: the role of angiogenesis and antiangiogenic therapy
Hematol Oncol Clin N Am
(2004)
MA Cobleigh et al.
A phase I/II dose escalation trial of bevacizumab in previously treated metastatic breast cancer
Semin Oncol
(2003)
American Cancer Society
Cancer Facts & Figures 2007
(2007)
KA Cronin et al.
Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis
J Natl Cancer Inst Monogr
(2006)
KD Miller
Recent translational research: antiangiogenic therapy for breast cancer-where do we stand?
Breast Cancer Res
(2004)
VEGF Overview
Genentech Web site
KD Miller et al.
Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane
Breast Cancer Res Treat
(2002)
Update on phase III ECOG E2100 trial: paclitaxel/bevacizumab in metastatic breast cancer
Cancer Abstracts and Summaries
(2006)
NK Ibrahim et al.
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
J Clin Oncol
(2005)
WJ Gradishar et al.
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
J Clin Oncol
(2005)

There are more references available in the full text version of this article.

Cited by (30)

Redox-responsive paclitaxel-pentadecanoic acid conjugate encapsulated human serum albumin nanoparticles for cancer therapy
2023, International Journal of Pharmaceutics
Human serum albumin (HSA) is an important nanocarrier of hydrophobic drugs due to its biocompatibility, bioresorbability, non-immunogenicity and intrinsic targetability. However, HSA/drug nanocomplexes have to experience complicated manufacturing process including multiple high-pressure homogenization and removing organic solvent under reduced pressure condition. Besides, the clinical application of these HSA/drug nanocomplexes is often limited because of their unsatisfactory stability and restricted dose. To overcome these issues, a redox-responsive paclitaxel-pentadecanoic acid prodrug conjugate embedded human serum albumin nanoparticles (NPs) was developed as a model in this report. First, PTX was activated and conjugated with 11-mercaptoundecanoic acid through a disulfide bond. The resultant disulfide bond bridged paclitaxel-pentadecanoic acid conjugate (PTX-SS-C10-COOH) was characterized by NMR and MS. After that, PTX-SS-C10-COOH dissolved in ethanol was mixed with HSA in water followed by lyophilization to generate HSA/PTX-SS-C10-COOH nanoparticles (HPTX NPs). Dynamic light scattering (DLS) and transmission electron microscopy (TEM) characterization indicated that the HPTX NPs have spherical structure with an average diameter of approximately 120 nm. The formation of HSA/PTX-SS-C10-COOH NPs was confirmed by fluorescence quenching technology, ascribed to electrostatic and hydrophobic interactions. The HPTX NPs displayed a high drug loading of 29.78 % and an entrapment efficiency of 94.16 %. Their reduced responsiveness was validated by glutathione (GSH)-triggered fast release of PTX. The pharmacokinetics, antitumor efficacy and systemic toxicity of HPTX NPs were thoroughly evaluated. The results showed that the HPTX NPs had longer retention, more effective tumor growth inhibition and lower toxicity compared with commercialized Taxol®. Importantly, the HPTX NPs could be administered at much high dose to achieve a significant tumor growth inhibition compared with Abraxane®. Together, the redox-responsive HPTX NPs with high drug loading is a promising strategy to deliver PTX for cancer chemotherapy.
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts
2016, Critical Reviews in Oncology/Hematology
Citation Excerpt :
In these studies, the ORR ranged from 36% (Link et al., 2007) to 76% (Lobo et al., 2010). Although a Q2W dosing schedule of nab-paclitaxel appeared to have an acceptable toxicity profile at doses up to 200 mg/m2 (Link et al., 2007; Lobo et al., 2010), treatment with nab-paclitaxel 260 mg/m2 Q2W in combination with bevacizumab (with filgrastim) given as first line therapy in 54 patients with human epidermal growth factor receptor-2 (HER2)-negative MBC resulted in unacceptable toxicity (grade ≥2 fatigue: 62%, bone pain: 23%) and led to the premature closure of that particular arm of the trial (Seidman et al., 2013). The feasibility of QW dosing of nab-paclitaxel was demonstrated in a phase I study of 39 patients with advanced non-haematological malignancies who received nab-paclitaxel 80–200 mg/m2 QW 3/4, with dose escalation according to a standard 3 + 3 design (Nyman et al., 2005).
The choice of chemotherapy for patients with metastatic breast cancer (MBC) depends on disease- and patient-related factors, but there is little guidance on dosing modifications for patients unable to receive the licensed dose. Nab-paclitaxel is a solvent-free form of paclitaxel that uses albumin as a drug carrier and exploits endogenous albumin transport pathways to achieve enhanced drug targeting and tumour penetration with reduced toxicity. It is approved for use at a dose of 260 mg/m² every three weeks in adults who have failed first-line treatment for MBC and for whom standard anthracycline-based therapy is not indicated. Emerging data suggest that weekly dosing schedules of nab-paclitaxel may provide clinical benefit in some patients, but the utility of these alternative dosing schedules remains unclear. A panel of breast cancer experts convened to review available literature for nab-paclitaxel in MBC and, taking into account their clinical experience, recommended that alternative dosing schedules may be considered according to the aggressiveness of disease and patient condition as follows: 125 mg/m² QW 3/4 (aggressive disease and fit), 100 mg/m² QW 3/4 (aggressive or indolent disease and unfit). All dosing schedules were considered acceptable for fit patients with indolent disease. These recommendations are based on current evidence, and emerging data from ongoing trials may reinforce or modify the recommendations provided.
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
2011, The Lancet Oncology
Citation Excerpt :
We previously reported that aflibercept was effective in preclinical models of ovarian cancer and had additive, and in some models, synergistic activity with taxanes.1,21,22 These data corroborate other results that have convincingly showed that taxanes, regardless of schedule, and anti-VEGF therapy have synergistic activity in various solid tumours.23–31 At clinically relevant doses, docetaxel produces serum concentrations that are associated with in-vitro tumour-cell apoptosis and antiangiogenic properties, such as endothelial-cell proliferation, migration, and capillary-tube formation.32,33
Biologically targeted therapies have been postulated as a viable strategy to improve outcomes for women with ovarian cancer. We assessed the safety, tolerance, pharmacokinetics, relevant circulating and image-derived biomarkers, and clinical activity of combination aflibercept and docetaxel in this population.
For the phase 1 (pharmacokinetic) study, eligible patients had measurable, recurrent or persistent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma with a maximum of two prior chemotherapy regimens. Aflibercept was administered intravenously over three dose levels (2, 4, or 6 mg/kg; one dose every 21 days) to identify the maximum tolerated dose for the phase 2 study. Pharmacokinetics were assessed and dynamic imaging was done during a lead-in phase with single-agent aflibercept (cycle 0) and during combination therapy with intravenous docetaxel (75 mg/m²). Eligibility for the phase 2 study was the same as for phase 1. Patients were enrolled in a two-stage design and given aflibercept 6 mg/kg intravenously and docetaxel 75 mg/m² intravenously, every 3 weeks. The primary endpoint was objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors version 1.0. The trial has completed enrolment and all patients are now off study. The trial is registered at ClinicalTrials.gov, number NCT00436501.
From the phase 1 study, the recommended phase 2 doses of aflibercept and docetaxel were found to be 6 mg/kg and 75 mg/m², respectively. Log-linear pharmacokinetics (for unbound aflibercept) were observed for the three dose levels. No dose-limiting toxicities were noted. 46 evaluable patients were enrolled in the phase 2 trial; 33 were platinum resistant (15 refractory) and 13 were platinum sensitive. The confirmed ORR was 54% (25 of 46; 11 patients had a complete response and 14 had a partial response). Grade 3–4 toxicities observed in more than two patients (5%) were: neutropenia in 37 patients (80%); leucopenia in 25 patients (54%); fatigue in 23 patients (50%); dyspnoea in ten patients (22%); and stomatitis in three patients (7%). Adverse events specifically associated with aflibercept were grade 1–2 hypertension in five patients (11%), and grade 2 proteinuria in one patient (2%).
Combination aflibercept plus docetaxel can be safely administered at the dose and schedule reported here, and is associated with substantial antitumour activity. These findings suggest that further clinical development of this combination in ovarian cancer is warranted.
US National Cancer Institute, US Department of Defense, Sanofi-Aventis, Gynecologic Cancer Foundation, Marcus Foundation, and the Commonwealth Foundation.
Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review
2011, Breast
Citation Excerpt :
While bevacizumab improved PFS in both studies, data for individual regimens remain unpublished. Within a cohort of 40 patients (85% treated previously for MBC), Link et al.17 retrospectively assessed outcomes following nab-paclitaxel (either 80–125 mg/m2 d1,8,15 q28d or 170–220 mg/m2 d1,15 q28d) + bevacizumab (10 mg/kg d1 q14d). Of 33 evaluable patients, 30% were HER2-positive and had progressed on trastuzumab; many HER2-positive individuals continued to receive trastuzumab during nab-paclitaxel + bevacizumab therapy.
Monotherapy with nanoparticle albumin-bound (nab)-paclitaxel has demonstrated improved efficacy and safety compared with solvent-based paclitaxel and docetaxel.
A comprehensive review of all reported studies of nab-paclitaxel combinations with other agents in all breast cancer settings was undertaken.
Most studies reviewed are small, phase II and non-comparative. Combinations studied included nab-paclitaxel plus trastuzumab and/or bevacizumab (with or without additional cytotoxic agents), gemcitabine, capecitabine, carboplatin, or lapatinib. The majority of metastatic and neoadjuvant studies demonstrated satisfactory efficacy and safety for nab-paclitaxel combinations, although conclusions regarding comparison with solvent-based taxane (SBT) regimens are not possible. The two adjuvant studies confirmed the safety of nab-paclitaxel combinations in this setting.
Although results of this review indicate that nab-paclitaxel may be an appropriate substitute for SBTs in combination regimens, additional research is required to confirm the place and cost effectiveness of these combinations before nab-paclitaxel could be recommended routinely in all settings.
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer
2011, Clinical Breast Cancer
Weekly administration of nanoparticle albumin-bound (nab) paclitaxel as a first-line treatment for metastatic breast cancer (MBC) has not been fully investigated. The addition of trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is less understood. This phase II study evaluated the efficacy and safety of weekly nab paclitaxel in the first-line MBC setting. Patients whose tumors overexpressed HER2 also received trastuzumab.
Patients with locally advanced or metastatic breast cancer received nab paclitaxel (125 mg/m²) by 30-minute intravenous infusion weekly for 3 of 4 weeks. Patients who were HER2-positive received concurrent trastuzumab.
Seventy-two patients were enrolled; HER2 expression was detected in 22 patients. The overall response rate (ORR) was 42.2% (95% CI, 30%–55%); 5 patients had a complete response (CR) and 22 patients had a partial response (PR). Additionally, 17 patients experienced stable disease (SD), providing an overall benefit (CR + PR + SD) of 68.8%. Patients with HER2-positive tumors had an ORR of 52.4%; the ORR was 38.1% in the HER2-negative population (P = .3). Median progression-free survival was 14.5 months (range, 1–49.3 months) and survival rates at 1 year and 2 years were 69% and 62%, respectively. The most commonly observed toxicities were pain (64%), fatigue (58%), sensory neuropathy (54%), infection (46%), nausea (38%), alopecia (33%), and anemia (33%).
Our findings demonstrate that weekly nab paclitaxel has a favorable safety profile and is well tolerated as a first-line treatment for MBC. An ORR of 42% and an overall benefit of 69% is extremely encouraging, particularly in the HER2-positive population where 52% of patients responded.
Novel cytotoxic backbones and targeted therapies: Recent data and ongoing clinical trials
2010, Clinical Breast Cancer
Novel therapies are emerging for treatment of patients with localized or advanced breast cancer. Targeted therapies such as trastuzumab, lapatinib, and bevacizumab have demonstrated significant clinical benefit in the metastatic setting, and trastuzumab has also improved patient outcome as adjuvant therapy in HER2⁺ breast cancer. Novel chemotherapies are also being developed to improve drug delivery, enhance efficacy, or decrease drug toxicity. These novel cytotoxic agents are being combined with established targeted therapies and are showing early promise for the treatment of patients with advanced breast cancer. Finally, new targeted therapies have shown clinical benefit, either as single agents or in combination with established targeted therapy or chemotherapy.

View all citing articles on Scopus

Electronic forwarding or copying is a violation of US and International Copyright Laws.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

View full text

Original ContributionBevacizumab and Albumin-Bound Paclitaxel Treatment in Metastatic Breast Cancer

Abstract

Background

Patients and Methods

Results

Conclusion

Hematol Oncol Clin N Am

Semin Oncol

Cancer Facts & Figures 2007

Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis

J Natl Cancer Inst Monogr

Recent translational research: antiangiogenic therapy for breast cancer-where do we stand?

Breast Cancer Res

Genentech Web site

Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane

Breast Cancer Res Treat

Update on phase III ECOG E2100 trial: paclitaxel/bevacizumab in metastatic breast cancer

Cancer Abstracts and Summaries

Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer

J Clin Oncol

Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer

J Clin Oncol

Original Contribution
Bevacizumab and Albumin-Bound Paclitaxel Treatment in Metastatic Breast Cancer